ROIV:NASDAQ
Roivant Sciences Ltd
$39.50
arrow_downward
-3.71%(-1.52) 1D
$39.52
arrow_upward
+0.05% (+0.020)bedtimeAfter hours
Closed: Sep 15, 4:00:00 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ROIV...
Open
$41.14
High
$41.14
Low
$39.22
Mkt. cap
28.53B
Avg. vol.
8.01M
Volume
8.10M
52-wk high
$42.50
52-wk low
$13.92
EPS
-$0.39
Beta
1.12
Shares outstanding
722.32M
No. of employees
721
Open
$41.14
High
$41.14
Low
$39.22
Mkt. cap
28.53B
Avg. vol.
8.01M
Volume
8.10M
52-wk high
$42.50
52-wk low
$13.92
EPS
-$0.39
Beta
1.12
Shares outstanding
722.32M
No. of employees
721
News stories
From web sources and news partners
Stock Titan
·
4 hours ago
Roivant Sciences (NASDAQ: ROIV) officer to sell 5,112 shares
Stock Titan
·
1 day ago
Roivant Sciences (ROIV) director uses stock to cover tax bill
Seeking Alpha
·
2 days ago
Roivant Sciences: Diverse Exposure To Biotech Niches Through Vants (NASDAQ:ROIV)
Profile
Roivant Sciences Ltd. is an American multinational healthcare company focused on applying technology to drug development and building subsidiary life sciences and health technology companies. It was founded in 2014 by Vivek Ramaswamy and is currently headed by CEO Matt Gline. Roivant maintains its headquarters in New York City as well as major offices in the biotech hubs of Boston and Basel. Wikipedia
About Roivant Sciences Ltd